New Drugs in the Pipeline for the Treatment of HIV: a Review

Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells

(2017) Yoshifumi Kobayashi et al.   JOURNAL OF GENERAL VIROLOGY

Targeting Class I Histone Deacetylases in a “Complex” Environment

(2017) Christopher J. Millard et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects

(2016) Didier Scherrer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Peginterferon α-2a for the treatment of HIV infection

(2016) David M Asmuth et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy

(2016) Marina Caskey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

(2016) Katharine J. Bar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Latency reversal and viral clearance to cure HIV-1

(2016) D. M. Margolis et al.   SCIENCE

Shocking HIV out of hiding

(2016) Thomas A. Rasmussen et al.   Current Opinion in HIV and AIDS

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

(2015) Jacob P Lalezari et al.   Lancet HIV

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV

(2014) Pablo Tebas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erasers of Histone Acetylation: The Histone Deacetylase Enzymes

(2014) E. Seto et al.   Cold Spring Harbor Perspectives in Biology

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Panobinostat in lymphoid and myeloid malignancies

(2013) Amit Khot et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Continuous versus intermittent treatment strategies during primary HIV-1 infection

(2012) Cécile Goujard et al.   AIDS

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

(2012) P. Tebas et al.   BLOOD

Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration

(2012) Livio Azzoni et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

(2012) R. E. Nettles et al.   JOURNAL OF INFECTIOUS DISEASES

Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial

(2010) François Boué et al.   AIDS

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

(2010) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial

(2010) David M. Asmuth et al.   JOURNAL OF INFECTIOUS DISEASES

Anti–HIV‐1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

(2010) Jeffrey M. Jacobson et al.   JOURNAL OF INFECTIOUS DISEASES

Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency

(2008) R. Pearson et al.   JOURNAL OF VIROLOGY